CervoMed Shares Drop 22% Following Early Phase 2a Data for Neflamapimod
CervoMed Inc. (CRVO) reported early 12-week trial results showing a reduction in plasma neurofilament light (NfL) levels among patients receiving its investigational drug, neflamapimod. Despite the biological biomarker findings from the Phase 2a study in non-fluent variant primary progressive aphasia (nfvPPA), shares of the company fell 22.05% to $2.51 on Tuesday.
In the 25-participant open-label trial, mean plasma NfL levels dropped by approximately 3.1 pg/mL, with most of the reduction occurring between weeks 6 and 12. A subgroup of 13 participants with baseline NfL levels at or above the median experienced a larger mean drop of roughly 5.7 pg/mL. Overall, 72% of participants had elevated baseline NfL, while levels of another biomarker, GFAP, remained stable. Neflamapimod was generally well tolerated, though one participant discontinued treatment due to elevated liver enzymes, which resolved after stopping the drug.
Biomarkers like NfL are used to track neurodegeneration, making early reductions a key focus for neflamapimod's development. Investors and clinical researchers will look ahead to November 2026, when CervoMed plans to present full 24-week biomarker data at the Clinical Trials on Alzheimer's Disease (CTAD) conference, followed by topline clinical outcome data expected in the first quarter of 2027.
Key points
- CervoMed Inc. reported a mean plasma NfL reduction of ~3.1 pg/mL over 12 weeks in a Phase 2a trial of neflamapimod.
- Participants with baseline NfL at or above the median saw a larger average reduction of ~5.7 pg/mL over 12 weeks.
- Neflamapimod was generally well tolerated, with one participant stopping due to elevated liver enzymes that later resolved.
- Shares of CervoMed Inc. (CRVO) fell 22.05% to $2.51 following the data release.
- CervoMed expects to present 24-week biomarker data at CTAD in November 2026 and release topline clinical data in Q1 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were the results of CervoMed's Phase 2a neflamapimod trial?
In initial 12-week data across 25 participants, mean plasma NfL fell by about 3.1 pg/mL, with most decline between weeks 6 and 12. Patients with higher baseline NfL saw a mean decline of about 5.7 pg/mL.
How did CervoMed stock react to the trial update?
Shares of CervoMed Inc. fell 22.05% to $2.51 following the release of the early trial data.
When will CervoMed report the next trial results for neflamapimod?
CervoMed plans to present 24-week biomarker data at the CTAD conference in November 2026, with topline clinical data expected in Q1 2027.